Ambient Temperature Stable, Scalable COVID-19 Polymer Particle Vaccines Induce Protective Immunity.

Abstract

There is an unmet need for safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines that are stable and can be cost-effectively produced at large scale. Here, a biopolymer particle (BP) vaccine technology that can be quickly adapted to new and emerging variants of SARS-CoV-2 is used. Coronavirus antigen-coated BPs are described as vaccines against SARS-CoV-2. The spike protein subunit S1 or epitopes from S and M proteins (SM) plus/minus the nucleocapsid protein (N) are selected as antigens to either coat BPs during assembly inside engineered Escherichia coli or BPs are engineered to specifically ligate glycosylated spike protein (S1-ICC) produced by using baculovirus expression in insect cell culture (ICC). BP vaccines are safe and immunogenic in mice. BP vaccines, SM-BP-N and S1-ICC-BP induced protective immunity in the hamster SARS-CoV-2 infection model as shown by reduction of virus titers up to viral clearance in lungs post infection. The BP platform offers the possibility for rapid design and cost-effective large-scale manufacture of ambient temperature stable and globally available vaccines to combat the coronavirus disease 2019 (COVID-19) pandemic.

• Authors: Shuxiong Chen, Benjamin Evert, Adetayo Adeniyi, Mercè Salla-Martret, Linda H-L Lua, Victoria Ozberk, Manisha Pandey, Michael F Good, Andreas Suhrbier, Peter Halfmann, Yoshihiro Kawaoka, Bernd H A Rehm
• Journal: Advanced healthcare materials (Adv Healthc Mater) Vol. 11 Issue 3 Pg. e2102089 (02 2022) ISSN: 2192-2659 [Electronic] Germany
• PMID: 34716678 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 Wiley-VCH GmbH.

Chemical References

• Antibodies, Viral
• COVID-19 Vaccines
• Polymers

Topics

• Animals
• Antibodies, Viral
• COVID-19
• COVID-19 Vaccines
• Cricetinae
• Humans
• Mice
• Polymers
• SARS-CoV-2
• Temperature